TVTX Canaccord raised the firm's price target on Travere Therapeutics to $62 from $56 and keeps a Buy rating on the shares. The firm updated

TVTX Canaccord raised the firm's price target on Travere Therapeutics to $62 from $56 and keeps a Buy rating on the shares. The firm updated its model ahead of Q2 results and noted 2Q26 is the first quarter where they expect to see revenue for Filspari in FSGS. They expect management to comment on how the launch is progressing, what they are seeing in terms of total Filspari PSFs, and draw comparisons to the previous launch in IgAN.